PMID- 14655518
OWN - NLM
STAT- MEDLINE
DCOM- 20040116
LR  - 20071114
IS  - 1399-543X (Print)
IS  - 1399-543X (Linking)
VI  - 4
IP  - 1
DP  - 2003 Mar
TI  - Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes 
      before and after disease onset.
PG  - 10-8
AB  - METHODS: We examined monocyte prostaglandin synthase 2 (PGS2/COX2) expression in 
      individuals at risk for or with type 1 diabetes including: (i) 58 established 
      type 1 and 2 diabetic patients; (ii) 34 autoantibody positive (AA+) children and 
      adults; (iii) 164 infants and young children with insulin-dependent diabetes 
      mellitus (IDDM) susceptibility human leukocyte antigen (HLA) alleles; and (iv) 37 
      healthy control individuals, over a 5-yr period. RESULTS: Established type 1 
      diabetic patients (1 month to 30+ yr post-disease onset) had significantly higher 
      PGS2 expression than healthy controls; by contrast, insulin-treated type 2 
      diabetic patients had significantly lower PGS2 expression than healthy controls. 
      Longitudinal studies of AA+ subjects at risk for type 1 diabetes indicated that 
      73% (11/15) of individuals who developed this disease during the study period 
      expressed high levels of PGS2 prior to or after onset. We also found high level 
      PGS2 expression in genetically at-risk infants and young children that correlated 
      with having a first-degree relative with type 1 diabetes, but not with age, 
      gender, or HLA genotype. In this population, high level PGS2 expression coincided 
      with or preceded autoantibody detection in 30% (3/10) of subjects. CONCLUSIONS: 
      These findings suggest that high level monocyte PGS2 expression, although subject 
      to fluctuation, is present in at-risk subjects at an early age and is maintained 
      during progression to and after type 1 diabetes onset.
FAU - Litherland, S A
AU  - Litherland SA
AD  - Department of Pathology, Immunology, and Laboratory Medicine, College of 
      Medicine, University of Florida, Box 100275, JHMHC, Gainesville, Florida 32610, 
      USA.
FAU - She, J X
AU  - She JX
FAU - Schatz, D
AU  - Schatz D
FAU - Fuller, K
AU  - Fuller K
FAU - Hutson, A D
AU  - Hutson AD
FAU - Peng, R H
AU  - Peng RH
FAU - Li, Y
AU  - Li Y
FAU - Grebe, K M
AU  - Grebe KM
FAU - Whittaker, D S
AU  - Whittaker DS
FAU - Bahjat, K
AU  - Bahjat K
FAU - Hopkins, D
AU  - Hopkins D
FAU - Fang, Q
AU  - Fang Q
FAU - Spies, P D
AU  - Spies PD
FAU - North, K
AU  - North K
FAU - Wasserfall, C
AU  - Wasserfall C
FAU - Cook, R
AU  - Cook R
FAU - Dennis, M A
AU  - Dennis MA
FAU - Crockett, S
AU  - Crockett S
FAU - Sleasman, J
AU  - Sleasman J
FAU - Kocher, J
AU  - Kocher J
FAU - Muir, A
AU  - Muir A
FAU - Silverstein, J
AU  - Silverstein J
FAU - Atkinson, M
AU  - Atkinson M
FAU - Clare-Salzler, M J
AU  - Clare-Salzler MJ
LA  - eng
GR  - 1RO1HD 37800/HD/NICHD NIH HHS/United States
GR  - P01-AI42288-03/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Denmark
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
RN  - 0 (Autoantibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Isoenzymes)
RN  - 0 (Membrane Proteins)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
SB  - IM
MH  - Adult
MH  - Autoantibodies/blood
MH  - Child, Preschool
MH  - Cyclooxygenase 2
MH  - Diabetes Mellitus, Type 1/*enzymology/genetics/immunology
MH  - Diabetes Mellitus, Type 2/enzymology
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA Antigens/genetics
MH  - Humans
MH  - Infant
MH  - Isoenzymes/*blood
MH  - Male
MH  - Membrane Proteins
MH  - Monocytes/*enzymology
MH  - Prostaglandin-Endoperoxide Synthases/*blood
EDAT- 2003/12/06 05:00
MHDA- 2004/01/17 05:00
CRDT- 2003/12/06 05:00
PHST- 2003/12/06 05:00 [pubmed]
PHST- 2004/01/17 05:00 [medline]
PHST- 2003/12/06 05:00 [entrez]
AID - PDI042 [pii]
AID - 10.1034/j.1399-5448.2003.00042.x [doi]
PST - ppublish
SO  - Pediatr Diabetes. 2003 Mar;4(1):10-8. doi: 10.1034/j.1399-5448.2003.00042.x.